But it was just last week that you were spouting off about how Alergan was going to buy AVNR because they were only 15 miles away. Now it's Novartis?
Oddly enough I do have a bit of TC. It's a small percentage of my trading portfolio. Somewhere around 2% or so.
Don't worry though I'll continue to drop in periodically though. If you wouldn't have wished me to go poof, I might have done just that.
Do you ever post anything that makes sense?
EBS forward P/E= 15
SGNT forward P/E= 38
INSY forward P/E= 14
AVNR forward P/E = not measurable due to lack of profits.
Yes, when/if AVNR starts to make money it too will have a measurable P/E.
You and greatdayforpumping keep slapping each other on the back posting your half truths. Attempting to discuss anything with either of you is like debating a brain damaged kinder gardener. You see what you want to see.
I never said AVNR is going to be profitable next year. Learn how to read. It may be, or may not be profitable. I simply don't care one way or another. I'm just calling out a couple pumpers for lies and half truths. If they stop posting BS, I'll go away.
As far a share price goes end of next year, why not go with the Carnival Barker's call of $250/shr? If you are going to dream, might as well dream big. Or course said, Carny Barker also called for break even in October of 2013 as well.
Let's take the 3 you singled out - Emergent, Sagent, and Insys.
What's the difference between those 3 and AVNR? Easy. All 3 are solidly profitable while AVNR is not, and will not be this year and possibly next.
EBS ~ $1.16/2014, $1.52/2015.
SGNT ~ $.14/2014 $.67/2015
INSY ~ $1.15/2014 $1.78/2015
AVNR ~ -$.30/2014 -$.17/2015 Note: those are losses. Has AVNR ever turned a profit in it's sad history?
I was an AVNR shareholder but bailed long ago when it became obvious there was a serious failure to launch. I made a nice profit for a couple months work. You? Not so much.
The only biotech I have at the moment is GILD. I'm currently up about 90% overall. More so in my IRA not quite as much in my trading account due to different purchase prices obviously.
Stop posting stupid stuff, and half truths, and I'll stop calling you out on it. Otherwise, I may never go away. I'll just drop in an yank your chain periodically. Fool.
I'm just going to pop in every now and again because I simply don't like lying pumpers like yourself and greatday. I was bored with this board but with an invite like that, I'm never going away.
"I read through Finston's response and was impressed. Like freedom of speech in off label selling,
the court gives freedom of speech top priority in these cases."
Whaaa???? There is no "freedom of speech in off label selling" period. The company and it's employees, this includes sales reps, can only promote/sell what is on the label. To do anything else is completely illegal. If a company is caught doing so, huge fines can result as well as potentially criminal prosecution. A doctor can legally prescribe "off label" if they feel it is medically necessary but the company cannot promote off label at all. Do not confuse off label use with off label promotion. They are definitely not the same thing. If a company wants to promote/sell for a different indication, then they need to get it on the label. There are no exceptions.
Just one example, Pfizer was fine $2.3B for off label promotion/selling of Bextra. Pfizer was promoting higher dosing and uses than what the label allowed and paid big time.
Yawn... Once again, the valuation or over valuation of one pharma is irrelevant to another. You are simply spouting nonsense that AVNR should be over valued as well because some other pharma is over valued. Non Sequitur.
I wouldn't touch any of those other over valued pharma either.
It seems like a normal response to me and it is no different than what TC management has been spouting for some time now. I have not heard anything from the company that says TC won't put TC mine on c&m end of year. The company is simply restating what they have been saying the whole time.
That being said, the likelihood of c&&m at end of year seems remote to me as long as molly prices stay above $10. I think once the business is done with the BLM, the story will change. Until then, I really don't see TC changing their tune even if it seems improbable. What else are they going to say? We are going to continue stripping even if we don't have approval?
Again, what do any of these have to do with AVNR? They certainly aren't competitors in any fashion. The market cap of another small cap pharma, whether wildly over priced or not, have zip to do with AVNR.
You have an absurd obsession with the valuation of Arena.
What exactly does Avanir have to do with Arena, other than they both start with "A"? Are you trying to imply that Avanir should be as ridiculously overvalued as Arena?
If another pharma were actually interested in partnering in Europe, they had the last 4 years to do so.
Stop making up rumors about AVNR being bought by Allergan.
Every time I've touched a dry shipper, I might as well of just put piles of money in the furnace and burn it. I hope you have better fortunes than I. As for myself, my normal playground is biotech. I've made great money in that space. It's usually a wild ride and you might lose most of your dollars but the winners far outweigh all the losers.
I'd be a seller and move on. The big gain is probably gone at that point. However, I'm not counting my dollars until if TC actually catches a bid. While it is possible, I don't see it happening any time soon. However, I'm not particularly prescient about these things so who knows maybe GG wants to become a CU and molly miner.
For now, I'm just sitting tight hoping molly prices stay where they are, CU creeps up a bit and gold doesn't tank. Other than that, just hope that TC executes smoothly, gets the tMeds out of the way, pays down some debt etc.